NO20082406L - Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen - Google Patents

Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen

Info

Publication number
NO20082406L
NO20082406L NO20082406A NO20082406A NO20082406L NO 20082406 L NO20082406 L NO 20082406L NO 20082406 A NO20082406 A NO 20082406A NO 20082406 A NO20082406 A NO 20082406A NO 20082406 L NO20082406 L NO 20082406L
Authority
NO
Norway
Prior art keywords
human platelet
monoclonal antibody
recognizes
platelet alloantigen
antibody
Prior art date
Application number
NO20082406A
Other languages
English (en)
Norwegian (no)
Inventor
Dominique Rigal
Jean Jacques Pin
Yves Merieux
Original Assignee
Diagnostische Forsch Stiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostische Forsch Stiftung filed Critical Diagnostische Forsch Stiftung
Publication of NO20082406L publication Critical patent/NO20082406L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20082406A 2007-06-22 2008-05-28 Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen NO20082406L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07012282A EP2006304A1 (fr) 2007-06-22 2007-06-22 Anticorps monoclonal anti-HPA-5b

Publications (1)

Publication Number Publication Date
NO20082406L true NO20082406L (no) 2008-12-23

Family

ID=38510463

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082406A NO20082406L (no) 2007-06-22 2008-05-28 Monoklonalt antistoff som gjenkjenner et humant blodplatealloantigen

Country Status (5)

Country Link
US (1) US8080242B2 (fr)
EP (1) EP2006304A1 (fr)
JP (1) JP2009013175A (fr)
AU (1) AU2008202154A1 (fr)
NO (1) NO20082406L (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
ES2610731T3 (es) * 2013-04-26 2017-05-03 Davos Diagnostics Ag Tipificaciones de aloantígenos plaquetarios y pruebas de anticuerpos plaquetarios
PL3126391T3 (pl) * 2014-03-31 2020-05-18 Universitetet I Tromsø - Norges Arktiske Universitet Przeciwciała przeciwko HPA-1a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516634A (en) * 1993-06-30 1996-05-14 Newman; Peter J. Molecular basis of the human platelet bra/brb alloantigen system and applications thereof
EP1916300A1 (fr) * 1995-08-29 2008-04-30 Kirin Pharma Kabushiki Kaisha Animal chimère et son procédé de construction
US5955266A (en) * 1996-04-01 1999-09-21 The Johns Hopkins University School Of Medicine Use of platelet polymorphism P1A2 to diagnose risk of thrombotic disease
US6210904B1 (en) * 1997-10-14 2001-04-03 Merck & Co., Inc. Anticoagulant test
US20030027207A1 (en) * 2000-02-29 2003-02-06 Filpula David Ray Anti-platelet binding proteins and polymer conjugates containing the same

Also Published As

Publication number Publication date
EP2006304A1 (fr) 2008-12-24
AU2008202154A1 (en) 2008-12-11
US8080242B2 (en) 2011-12-20
US20090117128A1 (en) 2009-05-07
JP2009013175A (ja) 2009-01-22

Similar Documents

Publication Publication Date Title
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
LTC2567976I2 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
CR20150102A (es) Anticuerpos que se unen a il-4 y/o il-13 (divisional 2)
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
WO2006099698A3 (fr) Nouvel anticorps anti-plgf
CY1115030T1 (el) Διειδικα αντι-vegf/αντι-ang-2 αντισωματα
PA8850201A1 (es) Combinaciones antitumorales que contienen anticuerpos
NO20084878L (no) Humanisert C-kit antistoff
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
CL2013000843A1 (es) Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
NO20065252L (no) Behandling av forstyrrelser
UY30776A1 (es) Anticuerpos cd44
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
NO20080246L (no) Anti-IGF1R-antistofformuleringer
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
NO20075845L (no) Fremgangsmate for behandling av inflammatorisk tarmsykdom (IBD) med et anti-CD20-antistoff
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
ME00261B (me) Tweak vezujuća antitijela
HN2006015949A (es) Anticuerpos de p-caderina
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
NI201100107A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente la cd38 y la citarabina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application